Compare BKT & PROF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BKT | PROF |
|---|---|---|
| Founded | 1988 | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 245.7M | 230.4M |
| IPO Year | N/A | N/A |
| Metric | BKT | PROF |
|---|---|---|
| Price | $11.01 | $7.39 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $11.00 |
| AVG Volume (30 Days) | 67.9K | ★ 142.9K |
| Earning Date | 01-01-0001 | 11-13-2025 |
| Dividend Yield | ★ 8.97% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $14,297,000.00 |
| Revenue This Year | N/A | $64.23 |
| Revenue Next Year | N/A | $113.06 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 67.94 |
| 52 Week Low | $10.55 | $3.76 |
| 52 Week High | $12.92 | $7.99 |
| Indicator | BKT | PROF |
|---|---|---|
| Relative Strength Index (RSI) | 45.08 | 57.66 |
| Support Level | $10.90 | $7.22 |
| Resistance Level | $11.09 | $7.95 |
| Average True Range (ATR) | 0.07 | 0.42 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 52.38 | 65.14 |
Blackrock Income Trust Inc is a diversified investment fund with an investment objective to manage a portfolio of high-quality securities to achieve both preservations of capital and high monthly income. The trust seeks to achieve its investment objective by investing at least 65 percent of its assets in mortgage-backed securities. The Fund invests at least 80 percent of its assets in securities that are (i) issued or guaranteed by the U.S. government or one of its agencies or instrumentalities or (ii) rated at the time of investment either AAA by S&P Global Ratings (S&P) or Aaa by Moody's Investors Service, Inc (Moody's). The Fund may invest directly in such securities or synthetically through the use of derivatives.
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of customizable, incision-free therapeutic systems for the image-guided ablation of diseased tissue utilizing its platform technologies and leveraging the healthcare system's existing imaging infrastructure. The company's product TULSA-PRO system combines real-time MRI, robotically driven transurethral sweeping-action thermal ultrasound with closed-loop temperature feedback control for the ablation of prostate tissue. The product is comprised of one-time-use devices and durable equipment that are used in conjunction with a customer's existing MRI scanner.